A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Acta Neurologica Belgica

• Publication date

  2001-12-01

• Fields of study

  Medicine

• Identifiers
  PMID 11851027
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of multiple sclerosis with mitoxantrone

  2005cited by this paper
• Escalating Immunotherapy with Mitoxantrone in Patients with Very Active Relapsing-Remitting or Progressive Multiple Sclerosis

  2000cited by this paper
• Corticosteroids or ACTH for acute exacerbations in multiple sclerosis.

  2000cited by this paper
• Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

  1997cited by this paper
• Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.

  1997cited by this paper
• Low‐dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis

  1995cited by this paper
• Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis

  1993cited by this paper
• Treatment of Multiple Sclerosis with Cyclophosphamide

  1992cited by this paper
• The efficacy of azathioprine in relapsing ‐ remitting multiple sclerosis

  1991cited by this paper
• Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group.

  1990cited by this paper
• Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group.

  1988cited by this paper
• Cyclosporine versus azathioprine in the long‐term treatment of multiple sclerosis—results of the german multicenter study

  1988cited by this paper
• La mitoxantrone, une nouvelle molécule anticancéreuse: pharmacologie, efficacité et tolérance

  1987cited by this paper
• Steroid therapy in multiple sclerosis. Point of view.

  1987cited by this paper
• Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone.

  1987cited by this paper
• Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone.

  1986cited by this paper
• Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function.

  1986cited by this paper
• Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice.

  1986cited by this paper
• Suppression of experimental allergic encephalomyelitis by mitoxantrone.

  1985cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper

• An overview on disease modifying and symptomatic drug treatments for multiple sclerosis

  2024cites this paper
• Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis.

  2023cites this paper
• Disease‐modifying therapies in multiple sclerosis: A focused review of rituximab

  2023cites this paper
• Multiple Sclerosis: Therapeutic Strategies on the Horizon

  2022cites this paper
• OVERVIEW OF MITOXANTRONE-A POTENTIAL CANDIDATE FOR TREATMENT OF BREAST CANCER

  2022cites this paper
• Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.

  2021cites this paper
• Re-examining the effects of high-dose intravenous methylprednisolone for secondary progressive multiple sclerosis.

  2021cites this paper
• Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.

  2020cites this paper
• Is there a new place for mitoxantrone in the treatment of multiple sclerosis?

  2020cites this paper
• Late Cardiotoxicity in MS Patients Treated with Mitoxantrone

  2019cites this paper
• Current immunotherapies for multiple sclerosis and neuromyelitis optica spectrum disorders: the similarities and differences

  2019influential citation
• Efficacy of rituximab in refractory RRMS

  2019cites this paper
• Diagnosis and management of secondary-progressive multiple sclerosis: time for change.

  2019cites this paper
• Efficacité et tolérance du Rituximab dans une cohorte de patients présentant une SEP rémittente avec activité inflammatoire persistante sous traitement de seconde ligne : étude observationnelle, rétrospective, multicentrique

  2017influential citation
• Autologous haematopoietic stem cell transplantation for neurological diseases

  2017cites this paper
• Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.

  2016cites this paper
• Neurotherapeutic Strategies for Multiple Sclerosis.

  2016cites this paper
• Evaluating the Role of Corticosteroid Pulse Therapy in Patients With Secondary Progressive Multiple Sclerosis Receiving Mitoxantrone: A Double Blind Randomized Controlled Clinical Trial

  2015cites this paper
• POLIMORFISMOS LINGO1 rs9652490 Y rs11856808 Y RIESGO PARA EL DESARROLLO DE ESCLEROSIS MÚLTIPLE

  2014cites this paper
• Management of disease‐modifying treatments in neurological autoimmune diseases of the central nervous system

  2014cites this paper
• The current role of mitoxantrone in the treatment of multiple sclerosis

  2014influential citation
• Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

  2013cites this paper
• Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis

  2013cites this paper
• Effektivität und Nebenwirkungen von Mitoxantron bei Multipler Sklerose in einer Langzeitbeobachtung über 10 Jahre

  2013cites this paper
• Mitoxantrone for multiple sclerosis.

  2013cites this paper
• Mitoxantrone-related acute leukemia in MS

  2013cites this paper
• Immunotherapy of Multiple Sclerosis

  2013cites this paper
• Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects.

  2012cites this paper
• Mitoxantrone in the treatment of multiple sclerosis: a single-center experience

  2012cites this paper
• Acute Therapies and Disease-Modifying Therapies for Multiple Sclerosis

  2012cites this paper
• The Influence of Pituitary, Adrenal, and Parathyroid Hormones on Hemostasis and Thrombosis

  2011cites this paper
• Managing MS in a changing treatment landscape

  2011cites this paper
• Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)

  2011cites this paper
• Disease-modifying therapy for multiple sclerosis in clinical practice

  2011cites this paper
• Managing relapsing–remitting multiple sclerosis following first drug failure

  2011cites this paper
• Handbook of Multiple Sclerosis

  2011cites this paper
• Hormones, haemostasis, and the risk of thrombosis

  2010cites this paper
• The influence of pituitary, adrenal, and parathyroid hormones on haemostasis and thrombosis

  2010cites this paper
• Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS

  2010cites this paper
• Comparative study of mitoxantrone efficacy profile in patients with relapsing—remitting and secondary progressive multiple sclerosis

  2010cites this paper
• Chemotherapeutics in the treatment of multiple sclerosis

  2010cites this paper
• Systematic review on the effect of glucocorticoid use on procoagulant, anti‐coagulant and fibrinolytic factors

  2010cites this paper
• Hormones, haemostasis, and the risk of thrombosis

  2010cites this paper
• Disease-modifying therapy

  2010cites this paper
• Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required

  2009cites this paper
• Endogenous opioids and multiple sclerosis

  2009cites this paper
• Restoring immune suppression in the multiple sclerosis brain.

  2009cites this paper
• Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies.

  2009cites this paper
• Mitoxantrone: benefits and risks in multiple sclerosis patients

  2009cites this paper
• Azathioprine in multiple sclerosis.

  2008cites this paper
• Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician.

  2008cites this paper
• Multiple Sclerosis: Critical Review of the Evidence for each Question

  2007cites this paper
• Critical Review of Existing Trials

  2007cites this paper
• Immunosuppressive agents in multiple sclerosis

  2007cites this paper
• Multiple Sclerosis and Demyelinating Diseases

  2007cites this paper
• Drug Class Review on Disease-modifying drugs for Multiple Sclerosis

  2007cites this paper
• Mitoxantrone in worsening secondary progressive multiple sclerosis: A prospective, open-label study.

  2006cites this paper
• Management of worsening multiple sclerosis with mitoxantrone: a review.

  2006cites this paper
• Therapeutic role of mitoxantrone in multiple sclerosis.

  2006cites this paper
• Therapeutic role of beta-interferons in multiple sclerosis.

  2006cites this paper
• Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro

  2005cites this paper
• Mitoxantrone for multiple sclerosis.

  2005cites this paper
• Immunosuppressive therapy for multiple sclerosis.

  2005cites this paper
• Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone

  2005cites this paper
• Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis

  2004cites this paper
• Multiple Sclerosis: Therapy

  2004cites this paper
• Review of mitoxantrone in the treatment of multiple sclerosis

  2004cites this paper
• Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.

  2004cites this paper
• Criteria to determine disability related to multiple sclerosis.

  2004cites this paper
• Mitoxantrone (Novantrone®) in multiple sclerosis: new insights

  2004cites this paper
• Immunmodulierende Therapiestrategien bei der multiplen Sklerose: Übersicht und aktueller Stand klinischer Studien

  2003cites this paper
• Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies

  2003cites this paper
• Management of multiple sclerosis: current trials and future options.

  2003cites this paper
• PRODUCT MONOGRAPH

  2000cites this paper